Replimune Group Inc —— 资产负债表 (NASDAQ:REPL) | MetaTrader

展开完整图表

Financials

概览声明统计

每季度年度

总资产 543.1 M461.19 M646.59 M487.72 M551.33 M 负债总额 44.37 M49.96 M91.3 M113.21 M135.49 M 权益总额 498.73 M411.23 M555.29 M374.51 M415.84 M 负债及股东权益总额 543.1 M461.19 M646.59 M487.72 M551.33 M 总债务 15.85 M—31.29 M47.53 M49.18 M 净债务 -460.45 M—-549.23 M-370.93 M-433.17 M

新闻

Undercovered Stocks: Zscaler, Aeluma, Devon Energy, And More

U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.63%

美国股市上涨；截至收盘道琼斯工业平均指数上涨0.63%

FDA Rejection Sparks Questions On Replimune Drug Approval Path - Replimune Group (NASDAQ:REPL)

Replimune Gets Second FDA CRL for Melanoma Drug BLA, Stock Crashes

Replimune: Second CRL May Have Sealed RP1's Fate - It's Hard To See Positives (REPL)

FDA Review Looms As Replimune Faces Weak Technical Setup - Replimune Group (NASDAQ:REPL)

Iovance Biotherapeutics: Positioned For Multi-Year Growth, Buy The Pullback (NASDAQ:IOVA)

RCKT Stock Down Despite FDA Nod to Gene Therapy in Rare Disease

CORT Rises on FDA Nod to Lifyorli in Platinum-Resistant Ovarian Cancer

Ocugen Falls as Gene Therapy for Eye Disease Lags in Phase II Study

ImmunityBio Rises on China Nod to Bladder Cancer Combo Therapy